Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Navarria, D. Baldaccini, E. Clerici, B. Marini, L. Cozzi, D. Franceschini, A. Bertuzzi, V. Quagliuolo, V. Torri, P. Colombo, C. Franzese, L. Bellu, M. Scorsetti (2022)
Stereotactic body radiation therapy (SBRT) for lung metastases from sarcoma in oligometastatic patients: a phase 2 study.International journal of radiation oncology, biology, physics
K. Ahmed, Jacob Scott, J. Arrington, A. Naghavi, D. Grass, B. Perez, J. Caudell, A. Berglund, E. Welsh, S. Eschrich, T. Dilling, J. Torres-Roca (2018)
Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation DoseJournal of Thoracic Oncology, 13
Onishi (2007)
S94J Thorac Oncol, 2
T. Treasure, F. Fiorentino, M. Scarci, H. Møller, M. Utley (2012)
Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry dataBMJ Open, 2
B. Baumann, S. Nagda, J. Kolker, W. Levin, K. Weber, A. Berman, A. Staddon, L. Hartner, S. Hahn, E. Glatstein, C. Simone (2016)
Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resectionJournal of Surgical Oncology, 114
P. Ferguson, B. Deheshi, P. Chung, C. Catton, B. O'Sullivan, Abha Gupta, A. Griffin, J. Wunder (2011)
Soft tissue sarcoma presenting with metastatic diseaseCancer, 117
(2007)
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study, 2
Jacob Scott, A. Berglund, M. Schell, I. Mihaylov, W. Fulp, B. Yue, E. Welsh, J. Caudell, K. Ahmed, T. Strom, E. Mellon, P. Venkat, P. Johnstone, J. Foekens, Jae Lee, E. Moros, W. Dalton, S. Eschrich, H. McLeod, L. Harrison, J. Torres-Roca (2017)
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.The Lancet. Oncology, 18 2
A. Filippi, F. Guerrera, S. Badellino, M. Ceccarelli, A. Castiglione, A. Guarneri, R. Spadi, P. Racca, G. Ciccone, U. Ricardi, E. Ruffini (2016)
Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer.Clinical oncology (Royal College of Radiologists (Great Britain)), 28 8
P. Navarria, A. Ascolese, L. Cozzi, S. Tomatis, G. D'agostino, F. Rose, R. Sanctis, A. Marrari, A. Santoro, A. Fogliata, U. Cariboni, M. Alloisio, V. Quagliuolo, M. Scorsetti (2015)
Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.European journal of cancer, 51 5
L. Okiror, A. Peleki, D. Moffat, A. Billé, E. Bishay, P. Rajesh, R. Steyn, B. Naidu, R. Grimer, M. Kalkat (2015)
Survival following Pulmonary Metastasectomy for SarcomaThoracic and Cardiovascular Surgeon, 64
(2021)
Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies, 112
(2011)
Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection, 117
B. Botz, Henry Knipe (2016)
OligometastasesRadiopaedia.org
Frakulli (2015)
5581Anticancer Res, 35
Y. Lee, K. Kang, H. Choi, I. Ha, Hojin Jeong, J. Song, I. Jang, Sung Kim, J. Lee, D. Rhee, B. Jeong (2018)
Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastasesThoracic Cancer, 9
N. Mehta, M. Selch, Pin-Chieh Wang, N. Federman, Jay Lee, F. Eilber, B. Chmielowski, N. Agazaryan, M. Steinberg, Percy Lee (2013)
Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade SarcomaSarcoma, 2013
M. Milano, A. Katz, M. Schell, A. Philip, P. Okunieff (2008)
Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.International journal of radiation oncology, biology, physics, 72 5
P. Cheung (2016)
Stereotactic body radiotherapy for oligoprogressive cancer.The British journal of radiology, 89 1066
D. Palma, R. Olson, S. Harrow, S. Gaede, A. Louie, C. Haasbeek, L. Mulroy, M. Lock, G. Rodrigues, B. Yaremko, D. Schellenberg, B. Ahmad, S. Senthi, A. Swaminath, N. Kopek, Mengxing Liu, K. Moore, S. Currie, R. Schlijper, G. Bauman, J. Labe, M. Qu, A. Warner, S. Senan (2020)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialJournal of Clinical Oncology, 38
J. Lodeweges, T. Klinkenberg, J. Ubbels, H. Groen, J. Langendijk, J. Widder (2017)
Long‐term Outcome of Surgery or Stereotactic Radiotherapy for Lung OligometastasesJournal of Thoracic Oncology, 12
Hellman (1995)
8J Clin Oncol, 13
A. Bezjak, R. Paulus, L. Gaspar, R. Timmerman, W. Straube, W. Ryan, Y. Garces, A. Pu, Anurag Singh, G. Videtic, R. Mcgarry, P. Iyengar, J. Pantarotto, J. Urbanic, A. Sun, M. Daly, I. Grills, P. Sperduto, D. Normolle, J. Bradley, H. Choy (2019)
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 15
J. Rieber, J. Streblow, L. Uhlmann, M. Flentje, M. Duma, I. Ernst, O. Blanck, A. Wittig, J. Boda-Heggemann, R. Krempien, F. Lohaus, N. Klass, M. Eble, D. Imhoff, H. Kahl, C. Petersen, S. Gerum, C. Henkenberens, S. Adebahr, P. Hass, E. Schrade, T. Wendt, G. Hildebrandt, N. Andratschke, F. Sterzing, M. Guckenberger (2016)
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".Lung cancer, 97
A. Lindsay, Edward Haupt, C. Chan, A. Spiguel, M. Scarborough, R. Zlotecki, Parker Gibbs (2018)
Treatment of Sarcoma Lung Metastases with Stereotactic Body RadiotherapySarcoma, 2018
R. Frakulli, F. Salvi, D. Balestrini, A. Parisi, M. Palombarini, S. Cammelli, M. Rocca, M. Salone, A. Longhi, S. Ferrari, A. Morganti, G. Frezza (2015)
Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas.Anticancer research, 35 10
H. Onishi, H. Shirato, Y. Nagata, M. Hiraoka, Masaharu Fujino, K. Karasawa, Y. Takai, T. Kimura, M. Hareyama, R. Hara (2007)
STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study
N. Chudgar, M. Brennan, R. Munhoz, P. Bucciarelli, K. Tan, S. D’Angelo, M. Bains, M. Bott, James Huang, Bernard Park, V. Rusch, P. Adusumilli, W. Tap, S. Singer, David Jones (2017)
Pulmonary metastasectomy with therapeutic intent for soft‐tissue sarcomaThe Journal of Thoracic and Cardiovascular Surgery, 154
G. Videtic, R. Paulus, Anurag Singh, Joe Chang, W. Parker, K. Olivier, R. Timmerman, R. Komaki, J. Urbanic, K. Stephans, S. Yom, C. Robinson, C. Belani, P. Iyengar, M. Ajlouni, D. Gopaul, Jorge Suescun, R. Mcgarry, H. Choy, J. Bradley (2017)
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.International journal of radiation oncology, biology, physics, 103 5
A. Freites-Martinez, N. Santana, S. Arias-Santiago, A. Viera (2020)
Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Side Effects of Antineoplastic Treatments.Actas dermo-sifiliograficas
Sughosh Dhakal, K. Corbin, M. Milano, A. Philip, D. Sahasrabudhe, Carolyn Jones, L. Constine (2010)
Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival.International journal of radiation oncology, biology, physics, 82 2
J. Widder, T. Klinkenberg, J. Ubbels, E. Wiegman, H. Groen, J. Langendijk (2013)
Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 107 3
R. Timmerman, Chen Hu, J. Michalski, J. Bradley, J. Galvin, D. Johnstone, H. Choy (2018)
Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung CancerJAMA Oncology, 4
Kyle Rusthoven, B. Kavanagh, S. Burri, Changhu Chen, H. Cárdenes, M. Chidel, T. Pugh, M. Kane, L. Gaspar, T. Schefter (2009)
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 10
Background: Lung metastases are the most common form of distant failure for patients diagnosed with sarcoma with metastasectomy considered for some patients with limited metastatic disease and good performance status. Alternatives to surgery such as stereotactic body radiation therapy (SBRT) can be considered, though data are limited. We present outcomes after SBRT for sarcoma lung metastases. Methods: Fifty sarcoma patients with 109 lung metastases were treated with SBRT between 2005 and 2021. Outcomes evaluated included local control (LC), overall survival (OS), and toxicity including lung pneumonitis/fibrosis, chest wall toxicity, dermatitis, brachial plexus, and esophageal toxicity. Systemic therapy receipt before and after SBRT was recorded. Results: SBRT schedules were divided into 3 cohorts: 30 to 34 Gy/1fx (n=10 [20%]), 48 to 50 Gy/4 to 5fx (n=24[48%]), and 60 Gy/5fx (n=16[32%]). With a median follow-up of 19.5 months, 1/3-year LC rates were 96%/88% and 1/3-year OS 77%/50%, respectively. There was no differences between the 3 regimens in terms of LC, OS, or toxicity. Size >4 cm was a predictor of worse LC (P=0.031) and worse OS (P= 0.039) on univariate analysis. The primary pattern of failure was new metastases (64%) of which the majority were in the contralateral lung (52%). One-year chemotherapy-free survival was 85%. Overall, 76% of patients did not require chemotherapy initiation or change of chemotherapy regimen after lung SBRT. Toxicity was reported in 16% of patients overall, including 25%, 20%, and 14% in the 30 to 34 Gy/1fx, 48 to 50 Gy/4 to 5fx, and 60 Gy/5fx cohorts, respectively. Conclusions: SBRT outcomes for lung metastases from sarcoma demonstrate high rates of LC and are similar with different dose/fractionation regimens. Lung SBRT is associated with prolonged chemotherapy-free survival. Prospective validation of these results is warranted.
American Journal of Clinical Oncology – Wolters Kluwer Health
Published: Jun 14, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.